The end really is nigh for Genasense in melanoma
This article was originally published in Scrip
Genta has finally put an end to the long and troubled development of its investigational antisense therapy Genasense for melanoma. While Harold Camping is just the latest in a series of false prophets predicting the end of the world, Genasense observers who had predicted the demise of the compound since before its first phase III melanoma failure back in 2004 have now been proved right.
You may also be interested in...
Clinical trial failures and holds for drugs derived from nucleic acids from Alnylam and Ionis join those of Dicerna and Genta as the hit rate for these drugs continues to degrade. The real question is whether the failures have been due to a lack of efficacy or safety.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.